Post hoc age-stratified analysis of the phase 3 True North trial and extension (1012 patients with ulcerative colitis): ozanimod safety was similar and efficacy generally comparable across ages, but not significant vs placebo in those over 60.
Secondary analysisn = 1,012
Faye et al. Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age